Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

Inside IPC’s International Fellowship Program: Francis Lai and Ricardo Romiti

Francis Lai, MBBS, FACD

Skin Health Institute

Melbourne, Australia

IPC Jr. Councilor

Bio

Ricardo Romiti, MD, PhD

University of Sao Paulo Brazil

São Paulo, Brazil

IPC Councilor

Bio

Psoriasis knows no borders—and neither does the pursuit of knowledge and collaboration. For Dr. Francis Lai, a 2023 IPC Fellow from Australia, and Professor Ricardo Romiti, his mentor in Brazil, the IPC International Fellowship Program was more than just an educational opportunity—it was a bridge connecting two countries, two healthcare systems, and two passionate advocates for psoriasis care.

Inspiration Behind the Journey

Dr. Lai’s path into dermatology began during his final year of medical school, inspired by the mentorship of Professor John Su. “It was eye-opening to see the breadth of dermatology, from pediatric conditions to surgical dermatology. But what stood out to me was how dermatology could profoundly improve patients’ lives,” he shared. Psoriasis, in particular, captured his interest because of its complex, systemic nature and the significant impact it has on patients’ quality of life.

“Psoriasis isn’t just a skin condition—it’s an inflammatory disease that affects both the body and mind,” Dr. Lai explained. “Recent advancements, especially in biologics and targeted therapies, have made it one of the most dynamic areas in dermatology.”

For Professor Romiti, the opportunity to mentor an IPC Fellow like Dr. Lai was equally exciting. “When (IPC CMO) Peter van der Kerkhof first told me Francis had requested to be matched with me, I was thrilled. A Fellow willing to travel across the globe to collaborate on a psoriasis project between Brazil and Australia sounded incredibly promising,” he recalled. “And that promise quickly became reality.”

A Fellowship Rooted in Collaboration

Dr. Lai’s decision to apply for the IPC Fellowship was fueled by the stories of past alums and having worked with IPC Councilors like Professor Peter Foley and Professor Jonathan Barker. “I saw how the Fellowship transformed past alumni’s careers and expanded their expertise. I wanted to experience that growth firsthand,” he said.

One of the most memorable parts of the Fellowship was Dr. Lai’s visit to Professor Romiti’s clinic at the Hospital das Clínicas of the FMUSP School of Medicine in São Paulo. “Spending three weeks there gave me invaluable insights into how psoriasis is managed in a different healthcare system. The diversity of cases—from inflammatory to aesthetic—and the warmth of the entire dermatology department made it an unforgettable experience,” he said.

Beyond the hospital, the mentorship extended into everyday life. “Ricardo and his family welcomed me with open arms. I even joined their jogging group and experienced my first traditional Brazilian barbecue—an all-day affair that definitely required pacing!” Dr. Lai laughed.

A Project with Global Impact

While the Fellowship was rich with clinical experiences, their collaborative research project truly highlighted the power of international partnership. Recognizing a gap in psoriasis epidemiology—particularly among Indigenous populations—Dr. Lai and Professor Romiti embarked on a global literature review.

“Data on psoriasis prevalence among Indigenous communities is extremely limited,” Professor Romiti explained. “We wanted to understand how geographical, environmental, genetic, and historical factors might influence prevalence, focusing on both Brazilian and Australian Indigenous populations. What we found was striking—an extremely low prevalence, likely due to environmental influences and genetic factors.”

Dr. Lai emphasized the significance of this work. “It’s not just about numbers—it’s about understanding disparities in healthcare access and ensuring Indigenous communities are included in future research and care strategies.”

Growth, Reflection, and Looking Ahead

Both Dr. Lai and Professor Romiti saw personal and professional growth throughout the Fellowship. “Francis’ dedication took our project beyond what I had anticipated,” said Professor Romiti. “We both learned so much—and had a lot of fun along the way.”

For Dr. Lai, the experience has already shaped his career path. Since returning to Australia, he’s taken on the role of academic lead at his hospital, establishing a clinical trials department and mentoring junior staff. He’s also been instrumental in launching Australia’s largest teledermatology service, providing nationwide access to dermatology care within two weeks.

“The Fellowship gave me a global perspective—it’s encouraged me to think beyond local challenges and contribute to the broader psoriasis community,” Dr. Lai reflected. “I hope to continue collaborating internationally and advocating for improved psoriasis care, particularly in underserved populations.”

As for Professor Romiti, the mentorship experience was equally rewarding. “This Fellowship didn’t just result in a successful project—it forged a fantastic friendship. And now, with Francis having a little daughter, we’re looking forward to welcoming his whole family to Brazil one day!”

“The Fellowship gave me a global perspective—it’s encouraged me to think beyond local challenges and contribute to the broader psoriasis community…I hope to continue collaborating internationally and advocating for improved psoriasis care, particularly in underserved populations.”

— Francis Lai, MBBS, FACD

Categories

Recent Posts

When Cancer and Psoriasis Coexist: New IPC Guidance Puts Clarity Where It Is Needed Most

Reframing Obesity in Psoriatic Disease: From Pharmacokinetic Barrier to Therapeutic Target

Psoriasis and Metabolic Health: What IPC’s Latest Publication Means for Clinical Practice

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026